Nuvectis CEO buys 12,500 shares at $20

Q: Was the Nuvectis Pharma (NVCT) insider purchase related to a public offering?

Yes. A footnote explains that Ron Bentsur bought 12,500 shares for $250,000 in the public offering announced on June 29, 2026, linking the insider purchase to that offering.

Nuvectis Pharma Chairman and CEO Ron Bentsur bought 12,500 shares of common stock at $20.00 per share in an open-market purchase tied to a public offering announced on June 29, 2026, for a total of $250,000.

Filing Impact

(High)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Nuvectis Pharma Chairman and CEO Ron Bentsur bought 12,500 shares of common stock at $20.00 per share in an open-market purchase tied to a public offering announced on June 29, 2026, for a total of $250,000.

After this transaction, he directly owns 3,688,424 shares of Nuvectis Pharma common stock, including shares of restricted common stock.

Insider Trade Summary

Net Buyer: 12,500 shares

Net Buy 1 txn

Insider BENTSUR RON

Role Chairman & CEO

Bought 12,500 shs ($250K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	12,500	$20.00	$250K

Holdings After Transaction: Common Stock — 3,688,424 shares (Direct)

Footnotes (2)

F1. Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026.
F2. Includes shares of restricted common stock.

Key Figures

Shares bought: 12,500 shares Purchase price: $20.00 per share Transaction value: $250,000 +2 more

5 metrics

Shares bought 12,500 shares Open-market purchase on June 30, 2026

Purchase price $20.00 per share Common stock transaction

Transaction value $250,000 12,500 shares in public offering

Shares after transaction 3,688,424 shares Total direct holdings following purchase

Net buy shares 12,500 shares Net buy direction in transaction summary

Key Terms

open-market purchase, restricted common stock, public offering, Form 4

4 terms

open-market purchase financial

"transaction_action: open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

restricted common stock financial

"Includes shares of restricted common stock."

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

public offering financial

"shares for $250,000 in the public offering announced on June 29, 2026"

A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nuvectis Pharma (NVCT) report on this Form 4?

Nuvectis Pharma reported that Chairman and CEO Ron Bentsur bought 12,500 shares of common stock at $20.00 per share, a $250,000 open-market purchase connected to a public offering announced June 29, 2026.

How many Nuvectis Pharma (NVCT) shares does Ron Bentsur own after this trade?

After the reported purchase, Ron Bentsur directly owns 3,688,424 shares of Nuvectis Pharma common stock. This total includes shares of restricted common stock, as noted in the Form 4 footnotes.

At what price did the Nuvectis Pharma (NVCT) CEO buy shares?

Ron Bentsur purchased Nuvectis Pharma common stock at $20.00 per share. The Form 4 describes this as an open-market purchase, totaling 12,500 shares for an aggregate value of $250,000.

What type of security did the Nuvectis Pharma (NVCT) insider acquire?

The filing shows Ron Bentsur acquired Nuvectis Pharma common stock. It also states that his post-transaction holdings include shares of restricted common stock within the total 3,688,424 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/01/2026 - 01:39 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENTSUR RON

(Last)

(First)

(Middle)

C/O NUVECTIS PHARMA, INC.

1 BRIDGE PLAZA, SUITE 275

(Street)

FORT LEE

NEW JERSEY

07024

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/30/2026		P		12,500⁽¹⁾	A	$20	3,688,424⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026.

2. Includes shares of restricted common stock.

	/s/ Ron Bentsur	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR